Navigation Links
Agendia's MammaPrint(R) Receives Prestigious Award From Dutch Innovation Platform
Date:6/26/2008

Test Declared One of the Most Pioneering Healthcare Innovations in 21st

Century

AMSTERDAM, Netherlands, June 26 /PRNewswire/ -- Agendia BV, a world leader in gene expression analysis-based diagnostics, is pleased to announce that the company recently received a prestigious award for its groundbreaking MammaPrint(R) test from the Dutch Innovation Platform. MammaPrint, a 70-gene signature diagnostic test that predicts high or low risk of breast cancer tumor recurrence, was chosen out of more than 150 entries as the most pioneering healthcare initiative and will have the distinguished honor of being actively supported at a national level by the Dutch government.

"We are honored that the value of MammaPrint has been recognized at a governmental level for its significant impact on the management of breast cancer," said Dr. Bernhard Sixt, president and chief executive officer of Agendia. "This award provides us with the national support that will ensure that even more breast cancer patients will benefit from personalized treatment."

MammaPrint was among four healthcare innovations awarded by Dutch Health Minister Ab Klink, chairman of the Healthcare Innovation Platform, at a recent Netherlands-based Healthcare summit. The Innovation Platform is the government's initiative dedicated to advancing The Netherlands toward becoming one of the top five international countries in the areas of higher education, research and innovation by creating the conditions, establishing the connections, and developing the vision required to stimulate innovation and entrepreneurship.

"Each year, more than 13,000 women are diagnosed with breast cancer in The Netherlands, with another 317,000 diagnosed throughout Europe and nearly 180,000 diagnosed in the United States," said Richard Bender, MD, FACP, Agendia's chief medical officer. "At Agendia, we are committed to making a positive impact on the health and quality of life of people suffering from cancer, and new technologies like MammaPrint are changing the way oncologists are treating this life-threatening disease in a way that directly benefits patients' lives."

As part of the recognition and support surrounding the award, Minister Klink noted that he would actively support the inclusion of MammaPrint in the package of treatments for which reimbursement is available so that the test can provide benefit to as many breast cancer patients as possible in The Netherlands.

About MammaPrint(R)

MammaPrint laboratory service is the first and only FDA cleared (February 2007) DNA microarray-based 'in vitro diagnostic multivariate index assay' (IVDMIA). MammaPrint measures the activity of 70 genes, providing information about the likelihood of tumor recurrence. The MammaPrint test measures the level of expression of each of these genes in a sample of a woman's surgically-removed breast cancer tumor and then uses a specific formula or algorithm to produce a score that determines whether the patient is deemed low risk or high risk for spread of the cancer to another site. The result may help a doctor in planning treatment and appropriate follow-up for a patient when used with other clinical information and laboratory tests. All MammaPrint tests are conducted in Agendia's CLIA-certified central service laboratory.

About Agendia

Agendia, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology. For more information on Agendia, please visit http://www.agendia.com.

* CupPrint(R) is based on a license to the TUO database of AviaraDx

MEDIA CONTACTS:

For Agendia - EU & non-U.S.-based Media:

Dr. Bernhard Sixt

President and Chief Executive Officer

Agendia

+31204621520

communications@agendia.com

For Agendia - U.S. Media:

Kelly Connor

Vice President

Ogilvy Public Relations Worldwide

+1.212.880.5328 Office

+1.609.221.5785 Mobile

Kelly.connor@ogilvypr.com


'/>"/>
SOURCE Agendia BV
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions
2. MammaPrint(R) Breast Cancer Test Validated in Lymph Node-Positive Breast Cancer Patients
3. TraumaCure Receives Prestigious ISO 13485 Certification
4. Kiwa Bio-Tech Receives Authorization From the Ministry of Commerce of the Peoples Republic of China to Wholesale Other Fertilizer Manufacturers Products
5. TraumaCure Receives Prestigious ISO 13485 Certification
6. Advance Nanotechs Owlstone Subsidiary Receives a $629,000 Order From Selex Galileo
7. WorldHeart Enters into a Recapitalization Agreement and Receives Bridge Financing
8. HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker
9. MEDRAD Receives FDA 510(k) Clearance for FDG Infusion System
10. Xenon Receives BIOTECanada Gold Leaf Award
11. Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017  MIODx announced today that it ... immunotherapy technologies from the University of California, San ... to monitor a patient for response to immune ... The second license extends the technology with a ... to have an immune-related adverse event (IRAE) from ...
(Date:2/23/2017)... upscale Capitol Hill neighborhood, with its swanky shops, parks and cafés, ... treatment salon to set up shop. But there,s Hair ... bistro on E Madison Ave, and CEO Maria Botham ... clinic, we pride ourselves on being a destination for parents ... stigma associated with lice. Everyone can get lice – it ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and ... or in healthcare facilities during periods of rest. A lightweight, non-invasive monitor is ...
(Date:2/23/2017)... ... February 23, 2017 , ... David ... Inventors Recognition Reception at Purdue Research Park of West Lafayette, Indiana. ... recognition of outstanding contributions to, and success with, commercializing discoveries from Purdue research. ...
Breaking Biology Technology:
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
(Date:1/24/2017)... Jan. 24, 2017  It sounds simple and ... that monitors vital signs and alerts parents on ... oxygen saturation level drops. But pediatric experts argue ... parents, with no evidence of medical benefits, especially ... marketed aggressively to parents of healthy babies, promising ...
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
Breaking Biology News(10 mins):